
Calculate your potential savings with our ROI Calculator
ROI Calculator
Picture the last time you reached for a simple adhesive bandage or a manual stethoscope. Although these tools feel ordinary, the U.S. Food and Drug Administration (FDA) still regulates them. Consequently, it regulates under the lightest level of oversight, known as Class I.
In the FDA’s three-tier system, therefore, Class I medical devices carry the lowest risk to patients and users. However, they must still meet specific rules to reach and stay on the market.
This guide breaks down everything you need to know about FDA Class I devices. Furthermore, we cover exemptions, regulatory requirements, labeling, and real-world examples. This knowledge will help you navigate compliance with confidence and get your product in caregivers’ hands faster.
The FDA assigns every medical device to one of three risk-based categories. This happens under Section 513 of the Federal Food, Drug, and Cosmetic (FD&C) Act and the implementing regulations in 21 CFR Parts 860–892. Class I represents the lowest-risk tier. A device falls into Class I when “general controls alone are sufficient to provide reasonable assurance of safety and effectiveness” — meaning no special or premarket approval controls are normally required.
In practical terms, if your product fits the definition of an existing Class I generic type and does not introduce new risks, you will likely follow the most streamlined regulatory path available—subject only to general controls, and often exempt from premarket notification requirements. (Those exemptions and their limits are covered in the next section.)
Even though Class I represents the lowest-risk tier, the FDA still expects manufacturers to follow general controls (registration, listing, labeling, complaint handling, and adverse-event reporting). The good news is that many higher-burden rules simply do not apply to most Class I products.
Understanding these exemptions lets manufacturers streamline time-to-market. Crucially, it streamlines processes without overlooking the baseline controls FDA still enforces. In the next section, we’ll map out every general control that does apply to Class I devices and how to satisfy them efficiently.
Under the FD&C Act and Title 21 of the Code of Federal Regulations (CFR), Class I devices must still meet “general controls.” This remains true even when many are exempt from 510(k) and most of Part 820. The essentials are outlined below, with the governing CFR parts and FDA links for deeper reference.
| Core Requirement | Key CFR Part(s) | What You Must Do | Notes for Class I Devices |
| Establishment Registration & Device Listing | 21 CFR 807 Subparts B–E | Register your facility with FDA and list every device you commercially distribute; verify or update each year between Oct 1 – Dec 31. | Applies to all Class I firms—no exemption. |
| Quality System Regulation (QSR) | 21 CFR 820 | Follow good manufacturing practice. Most Class I devices gain exemption from design controls and other subparts. However, records (§ 820.180) and complaint files (§ 820.198) always apply. | Check your device’s specific entry in 21 CFR 862–892 to confirm the exact scope. |
| General & UDI Labeling | 21 CFR 801; 21 CFR 830 | Provide an accurate label that includes manufacturer info, intended use, and any required warnings. As of Sept 24 2023, Class I devices must also bear a Unique Device Identifier (UDI) unless specifically excepted. | OTC instructions, IFU, and language requirements still apply. |
| Medical Device Reporting (MDR) | 21 CFR 803 | Submit a report within 30 calendar days of learning your device may have caused or contributed to a serious injury, or immediately if a death has occurred. | Importers and user facilities have parallel duties; voluntary reporting remains encouraged. |
| Corrections & Removals | 21 CFR 806 | Notify the FDA within 10 working days if you initiate a field correction or removal to reduce a risk to health or remedy a legal violation. | Not required if the action is solely a market-quality enhancement or already reported under MDR. |
Meeting these general controls is the price of market entry—skip them and FDA can detain imports, issue warning letters, or mandate recalls even for low-risk devices. In the next section, we’ll walk through the streamlined approval pathway (or lack thereof) most Class I products enjoy and the small subset that still require a 510(k).
The word “approval” is a misnomer for most Class I products. What the FDA requires is either simple listing (for the 510(k)-exempt majority) or a streamlined premarket notification [510(k)] for the small group of “Reserved” devices.
| Regulatory Pathway | Who Must Follow It | Core Steps (in order) | Statutory / Typical Timeline | Endpoint |
| Exempt Listing (≈ 93 % of Class I devices) | Any device whose regulation in 21 CFR Parts 862-892 states “510(k) exempt.” | 1. Establishment Registration in FDA Unified Registration & Listing System (FURLS). 2. Device Listing—identify the product code and regulation number. 3. Implement required general controls (records, labeling, MDR, etc.). |
Registration & listing must be completed before commercial distribution; update annually (Oct 1 – Dec 31). | Device may be marketed immediately once listing is active. |
| 510(k) Clearance (“Reserved” Class I devices—≈ 50 types) | Products specifically marked “Reserved” in their CFR entry or that exceed exemption limits (e.g., novel indications). | 1. Confirm “Reserved” status in Medical Device Exemptions 510(k) & GMP database. 2. Prepare an electronic 510(k) using the eSTAR template (mandatory for submissions after Oct 1 2023). 3. Pay user fee (discounted small-business rate if qualified). 4. Submit via CDRH Portal or ESG. 5. FDA Acceptance Review (≤ 15 days) → Substantive Review (goal 60 days) → Final decision (statutory 90 days). |
~90 FDA days (clock pauses for Additional Information requests). | FDA issues a 510(k) clearance letter; firm can then list and market. |
With the pathway confirmed, the next compliance hurdle is labeling. Even Class I devices face detailed rules here. Therefore, the following section drills into Part 801 and UDI obligations you must meet before shipping the product.
Even the lowest-risk devices may see a pull from the market if the label is wrong. FDA treats mislabeling as misbranding under Sections 502(a) and 502(f) of the FD&C Act. Consequently, every Class I firm must follow the device-labeling framework in 21 CFR Part 801 and, for unique device identifiers, 21 CFR Part 830.
Tip! Keep wording and fonts legible at the point of use; Part 801 does not dictate font size, but inspectors cite firms when small or glossy text is unreadable.
Deadline met: All Class I device labels and packages produced on or after Sept 24 2023 must carry a UDI\. In addition, they require listing in the Global UDI Database (GUDID), unless a specific exception or alternative applies.
| Scenario | Key Section | What to Include | Notes |
| In-process sterile goods shipped to contract sterilizer | § 801.150(e) | Prominent “Unsterilized—For Sterilization Only” statement; agreement on handling | Prevents unsterile products from reaching users. fda.gov |
| OTC devices sold retail | § 801.61–801.62 | Net quantity, retail-oriented instructions, and any graphics needed for lay users | Must be understandable by non-professionals. |
| Prescription-only Class I devices (rare) | § 801.109 | “Rx Only” legend in a box or standout type | Directions for professional use may be supplied separately. |
FDA permits e-IFU only for specific hospital-use devices or under enforcement discretion. Class I manufacturers should assume a paper IFU is required unless qualifying under a declared electronic-labeling guidance.
6. Common Pitfalls Cited in FDA 483s
A Class I label may look simple, but every line sees governance by Parts 801 and 830. Treat label creation like any other controlled process. Specifically, verify elements, affix a compliant UDI, retain proof, and you’ll avoid the misbranding trap. Next, we’ll anchor these requirements with concrete product examples to show how they apply in the real world.
Below are three concrete examples straight from an FDA device-classification briefing. Together, they illustrate how wide-ranging—and generally low-risk—Class I products prove themselves to be.
These examples underscore the diversity of Class I devices: everyday wound-care supplies, basic surgical tools, and even routine lab reagents can all share the same low-risk regulatory tier when general controls alone assure safety and effectiveness.
The FDA makes it clear: even the lowest-risk devices must comply with general controls—registration, listing, labeling, complaint files, records, and (when applicable) good manufacturing practices. Qualityze’s cloud-native EQMS automates those touch-points. Thus, you can meet every item in 21 CFR without drowning in spreadsheets.
Electronic change-control links label revisions to risk assessments. This prevents untracked edits that could trigger misbranding findings.
Even when most of Part 820 is exempt, § 820.180 (records) and § 820.198 (complaint files) remain. Qualityze delivers both out of the box, with electronic signatures and full audit trails aligned to current GMP principles.
If you must repair, replace, or refund under Section 518, Qualityze CAPA system ties corrective actions to affected lots and auto-generates customer-notification lists, streamlining recall-class determinations.
General controls may be lighter than a PMA, but they are still far-reaching. Qualityze EQMS Suite weaves each requirement from the FDA’s General Controls for Medical Devices into an integrated, traceable workflow. This helps Class I manufacturers stay market-ready without excessive administrative overhead.
See it in action by requesting a free demo.
Author

Qualityze Editorial is the unified voice of Qualityze, sharing expert insights on quality excellence, regulatory compliance, and enterprise digitalization. Backed by deep industry expertise, our content empowers life sciences and regulated organizations to navigate complex regulations, optimize quality systems, and achieve operational excellence.